RELAÇÃO DE GALECTINA 4 E ADENOCARCINOMA DUCTAL PANCREÁTICO: UMA REVISÃO INTEGRATIVA

RELATIONSHIP OF GALECTIN 4 AND PANCREATIC DUCTAL ADENOCARCINOMA: AN INTEGRATIVE REVIEW

Authors

DOI:

https://doi.org/10.18616/inova.v14i5.8582

Abstract

ABSTRACT

 

The present study aims to discuss the influence of galectin 4 on the progression of Pancreatic Ductal Adenocarcinoma (PDAC). The integrative review model was employed, through a literature review, as the methodological approach. Galectin-4 (Gal-4), a β-galactoside binding protein, plays a significant role in pancreatic cancer. Expressed in several types of cancer, including colorectal, breast, gastric, lung and pancreatic, Gal-4 emerges as a possible biomarker and therapeutic target. Its action in colorectal cancer, by inhibiting progression, is in line with its function in pancreatic ductal adenocarcinoma, where it plays an inhibitory role in cell migration. Mechanisms involve modulation of the Wnt/β-catenin and IL-6/NF-κB/STAT3 pathways. Gal-4 expression correlates with cell-tumor and red blood cell interactions, indicating implications for tumor dissemination. Present in precursor lesions and chronic pancreatitis, Gal-4 stands out as a marker in early or inflammatory stages. Results from models and clinical studies offer valuable insights regarding the expression of Gal-4, its effects on cell signaling pathways and possible correlations with relevant clinical parameters in the context of PDAC. Future investigations should elucidate mechanisms, interactions, and clinical relevance, supporting effective therapeutic and diagnostic strategies in PDAC.

 

Keywords: Cancer, Galectins, PDAC.

Downloads

Download data is not yet available.

Published

2024-06-28